グルタミン酸受容体相互作用タンパク質GRIP1は,キネシンをデンドライトに直接誘導する
Mitsutoshi Setou1, Dae-Hyung Seog, Yosuke Tanaka
1Department of Cell Biology and Anatomy, Graduate School of Medicine, University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan.
Nature
|May 3, 2002
まとめ
GluR2相互作用タンパク質 (GRIP1) は,直接キネシンモーターを誘導し,α-アミノ-3-ヒドロキシ-5-メチルイソクサゾール-4-プロピオネート (AMPA) 受容体をニューロン dendrites に誘導します. このタンパク質とモーターの相互作用が,神経機能にとって極めて重要な輸送方向を決定する.
科学分野:
- 細胞生物学 細胞生物学
- 神経科学は神経科学である.
- 分子生物学は分子生物学である.
背景:
- 分子モーターは細胞内輸送に不可欠ですが,その操縦メカニズムは不明です.
- 神経細胞では,キネシンモーターがベジクルを輸送し,貨物が正しい局所化のためにモーター機能を指示する可能性があることを示唆しています.
研究 の 目的:
- キネシンモーターが特定のニューロン部位にどのように誘導されるかを調査する.
- タンパク質が,キネシンのようなモータータンパク質を直接制御できるかどうかを判断する.
主な方法:
- AMPA受容体サブユニットGRIP1とキネシン重鎖の相互作用を研究した.
- ネズミのモデルで遺伝子ターゲティングとドミナントネガティブ実験を活用した.
- 相互作用ドメインの操作後にキネシンとGRIP1の局所化を調べました.
主要な成果:
- GRIP1が重鎖に直接結合し,運動を制御することを示した.
- GRIP1は,AMPA受容体のキネシン媒介による輸送をデンドライトに誘導することを示した.
- キネシン重鎖操作で異常なGRIP1局所化が観察されました.
- GRIP1の発現は,JSAP1のソマトアキソナルパターンとは異なる,ソマトデンドリティックキネシン蓄積につながることを発見しました.
結論:
- GRIP1のような直接結合タンパク質は,モータータンパク質の交通方向を決定することができます.
- このメカニズムは,特にAMPA受容体密輸のために,ニューロン内の分子の偏極化された分類に不可欠です.
関連する概念動画
Activation and Inactivation of G Proteins
8.9K
Heterotrimeric G proteins are guanine nucleotide-binding proteins. As the name suggests, heterotrimeric G proteins are composed of three subunits: alpha, beta, and gamma. They remain GDP-bound or GTP-bound inside the cells and switch between inactive/active states. The Gα subunit possesses the nucleotide-binding pocket that binds guanine nucleotides and switches between GDP or GTP-bound states. In contrast, the Gꞵ and Gγ subunits are always bound together with high...
8.9K
GPCR Desensitization
6.2K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.2K
Integrins
4.8K
Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
4.8K
Ligand-Gated Ion Channel Receptor: Gating Mechanism
4.6K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
4.6K
Oral Hypoglycemic Agents: Glinides
1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K


